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background:  The prevalence of hypertension is 32% in the US; 8.9% of these patients may suffer from resistant hypertension (RHT), defined as 
uncontrolled blood pressure, despite >3 antihypertensive medications at optimal doses. RHT results in high medical costs associated with increased 
cardiovascular (CVD) events and end-stage renal disease (ESRD). This analysis assessed the clinical and economic impact of the Vessix System for 
renal denervation (RDN) compared to best medical therapy (BMT) in patients with RHT.
methods:  A Markov model was developed comparing RDN to BMT. Major adverse clinical outcomes associated with elevated systolic blood 
pressure (SBP) were modeled: Coronary heart disease, stroke, congestive heart failure, ESRD, and death. The patient profile in the model was similar 
to that in the Vessix REDUCE HTN trial: baseline SBP 182mm Hg, mean age 59, and 27% diabetic, mean office based SBP reduction of 24.6 and 
29.6 mm Hg at 6 and 12 months, respectively. These patients have a 36% risk of CVD over 10 years. The impact of SBP reduction on CVD events and 
ESRD was derived using relative risks from published literature and costs estimates from US DRG and CPT costs.
results:  RDN increased life expectancy and was cost- effective at both 10 years and lifetime.
conclusions:  This model suggests RDN is a cost effective strategy with mortality improvement for RHT compared to BMT alone. These results 
should be considered when developing policy and establishing the value for this minimally invasive technology.
Table 1. Results of Cost Effectiveness Analysis at 10 Years and Lifetime
10 Years Lifetime
Incremental costs $6,811 $3,724
Adverse events avoided 0.37 0.53
Incremental life years gained 0.36 1.41
Incremental cost per life years gained $18,819 $2,637
